Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217737 · ClinicalTrials.gov registry record · Phase 3
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
A Phase 3 study of Colon Adenocarcinoma and Stage IIA Colon Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 2,431
- Enrollment target
- 20
- Study locations
NCT00217737 is a Phase 3 study of Colon Adenocarcinoma and Stage IIA Colon Cancer AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 2,431 participants, above the 505-participant average among 11 other Colon Adenocarcinoma trials with a reported enrollment target (381% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00217737, a Phase 3 study of Colon Adenocarcinoma and Stage IIA Colon Cancer AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,431 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies oxaliplatin, leucovorin, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Oxaliplatin
- BIOLOGICAL Bevacizumab
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mills-Peninsula Medical Center - Burlingame
- East Bay Radiation Oncology Center - Castro Valley
- Eden Hospital Medical Center - Castro Valley
- Valley Medical Oncology Consultants-Castro Valley - Castro Valley
- John Muir Medical Center-Concord - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Bay Area Breast Surgeons Inc - Emeryville
- Valley Medical Oncology Consultants-Fremont - Fremont
Alabama
- Northeast Alabama Regional Medical Center - Anniston
- University of Alabama at Birmingham Cancer Center - Birmingham
- Clearview Cancer Institute - Huntsville
- Mobile Infirmary Medical Center - Mobile
- Providence Hospital - Mobile
Arizona
- Mayo Clinic in Arizona - Scottsdale
- Banner University Medical Center - Tucson - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- NEA Baptist Memorial Hospital - Jonesboro
Alaska
- Providence Alaska Medical Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,431 participants |
| Start Date | 2005-09-06 |
| Est. Completion | 2026-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217737
The ClinicalTrials.gov registry entry for NCT00217737 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,431 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 505-participant average among 11 other Colon Adenocarcinoma trials with a reported enrollment target (381% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colon Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Fluorouracil is the first listed.
NCT00217737 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00217737 about?
NCT00217737 is a clinical study titled "Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer". This randomized phase III trial studies oxaliplatin, leucovorin, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, l...
What is the current status of trial NCT00217737?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,431 participants. The study started on 2005-09-06. Estimated completion is 2026-04-11.
What conditions does trial NCT00217737 study?
This clinical trial studies the following conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7.
What interventions are being tested in trial NCT00217737?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00217737?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00217737 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
ACTIVE NOT RECRUITING · Phase 3
-
Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
RECRUITING · Phase 2
-
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
RECRUITING · Phase 1
-
Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.